focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-UK for sale

Fri, 09th Jul 2021 09:59

Welcome to the home for real-time coverage of markets brought to you by Reuters stocks
reporters.

UK FOR SALE (0859 GMT)

There's been a burst of M&A activity in the UK in recent weeks, with Spire Healthcare
, Morrison Supermarkets and Vectura all being targeted. But then there
were tons of other private deals as well throughout the year.

The value of UK Plc acquisitions (pending and completed ones) has soared to $176 billion so
far in 2021, nearly double of the same period in 2020, according to Refinitiv data.

What's more, British blue chip stocks are the only ones among developed market peers to have
not scaled back pre-pandemic peak. They are one of the cheapest out there on a forward
price-to-earnings basis. Let's not forget, UK also tops the charts on dividend pays.

Those deals are a welcome relief for UK stock markets, which have heavily underperformed
European and U.S. stocks since the Brexit referendum.

(Thyagaraju Adinarayan)

*****

TRAVEL STOCKS BOOST EUROPE AT OPEN (0723 GMT)

Europe's STOXX 600 rises 0.8% as bond markets calm down and some of the cyclical
names bounce after yesterday's brutal selloff.

Travel stocks were top sectoral gainers (+2%) as the UK further relaxed quarantine rules. In
the coming weeks, it's set to scrap quarantine for fully-vaccinated arrivals from other
countries.

Bond proxy sectors telecom and utilities were among the underperformers after recent rally.

Among single stocks, Vectura jumps 12.5% after cigarette maker Philip Morris outbid PE firm
Carlyle to buy the British pharma company.

(Thyagaraju Adinarayan)

*****

YOU NEED TO CALM DOWN... (0651 GMT)

In a week that's seen U.S. Treasury yields dive as much as 20 basis points in three sessions
and European stocks suffer one of their worst days in two months, perhaps investors are heeding
the words from Taylor Swift's "You need to calm down."

Stock futures point to a brighter start for Europe, where indices were a sea of red just a
day ago. U.S. 10-year Treasury yields are up 5 bps -- a sign that the relentless push into
safe-haven debt markets of the last few days is abating.

Okay, so Asian shares are languishing at two-month lows on concerns that the spread of Delta
variants will hurt world growth. But compared to the last few sessions, a sense of calm finally
appears to be taking hold as the week draws to an end.

With the idea that reflation is dead or at least taking a break for now and surging variants
of COVID-19 cast a shadow over the global economic recovery, a rethink has clearly taken place
among investors.

Thursday's decision by the European Central Bank to set a new 2% inflation target, versus a
previous below but close to 2%, left markets unfazed but was generally seen as pointing to an
even longer period of central bank stimulus.

For some, the scale of the fast and furious moves in bond markets have gone too far and
reflect a shake-out in positioning rather than a real shift in underlying economic conditions.
Time will tell.

The Biden administration is set as early as Friday to add more than 10 Chinese companies to
its economic blacklist over alleged human rights abuses and high-tech surveillance in Xinjiang,
two sources told Reuters.

Any signs of resurgent tensions between the world's two biggest economies could of course
quickly send investors back into safe-haven assets.

Key developments that should provide more direction to markets on Friday:

- China's factory gate inflation slows

- Morgan Stanley faces data breach, corporate client info stolen in vendor hack

- UK economy grew by slower-than expected 0.8% in May

- UK May industrial output up 0.8% in m/m

- Canada June unemployment rate.

- ECB Andrea Enria participated in panel discussion

- Fitch Ratings review on Russia, Lithuania

- G20 kick off two-day summit in Venice, Italy.

(Dhara Ranasinghe)

*****

MORNING CALL: IT'S SETTLING DOWN A BIT

European stocks are set to edge higher after one of their worst days in 2021 as the rally in
U.S. Treasuries this week cools. Volatility has also receded with the Wall Street 'fear guage'
VIX closing at 19 points after exceeding 20 on Thursday.

Those moves have killed the momentum in reflation trade and some analysts believe we've
probably alread seen the best of it. The global spread of the Delta virus variant has spooked
investor confidence across the world.

"Yesterday’s continued slide in bond yields, along with a sharp fall in stock markets,
appears to be painting a narrative that the reflation trade is dead or dying," says Michael
Hewson, chief market analyst at CMC Markets UK.

In the corporate world, Airbus said its jet deliveries rose 52% in the first-half.

Another interesting story is how UK supermarkets are super-stretched by soaring demand for
beer, soft drinks, salads and barbecue food as England supporters prepare for Sunday's Euro 2020
final.

(Thyagaraju Adinarayan)

*****

More News
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more
4 Dec 2020 13:05

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

Read more
30 Nov 2020 09:53

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Read more
30 Nov 2020 08:06

Vectura signs asthma treatment deal with Kinaset

(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.

Read more
20 Nov 2020 08:34

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

Read more
19 Nov 2020 20:25

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
15 Sep 2020 17:22

Vectura Revenue Slips But Swings To First Half Profit

Vectura Revenue Slips But Swings To First Half Profit

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
2 Sep 2020 19:36

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

Read more
7 Jul 2020 16:35

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

Read more
9 Jun 2020 12:04

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

Read more
8 Jun 2020 15:00

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.